Comment
doi: 10.7326/J22-0038.
Epub 2022 Jun 7.
In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death
Affiliations
- PMID: 35667068
- DOI: 10.7326/J22-0038
Item in Clipboard
Comment
In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death
Ann Intern Med.
2022 Jun.
Abstract
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397-408. 35172054.
Comment on
-
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
Similar articles
-
Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.JAMA Netw Open. 2023 Apr 3;6(4):e2310887. doi: 10.1001/jamanetworkopen.2023.10887. JAMA Netw Open. 2023. PMID: 37103932 Free PMC article.
-
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019.Clin Infect Dis. 2023 Feb 18;76(4):563-572. doi: 10.1093/cid/ciac673. Clin Infect Dis. 2023. PMID: 35986628 Free PMC article.
-
[In symptomatic, nonhospitalized unvaccinated adults with mild to moderate COVID-19 at risk for progression to severe disease, does nirmatrelvir/ritonavir decrease the risk of COVID-19-related hospitalization or all-cause mortality while being safe?].Rev Med Interne. 2022 Apr;43(4):270-271. doi: 10.1016/j.revmed.2022.02.008. Epub 2022 Feb 28. Rev Med Interne. 2022. PMID: 35279350 Free PMC article. French. No abstract available.
-
Nirmatrelvir Plus Ritonavir: First Approval.Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5. Drugs. 2022. PMID: 35305258 Free PMC article. Review.
-
First-generation oral antivirals against SARS-CoV-2.Clin Microbiol Infect. 2022 Sep;28(9):1230-1235. doi: 10.1016/j.cmi.2022.04.015. Epub 2022 May 8. Clin Microbiol Infect. 2022. PMID: 35545195 Free PMC article. Review.
Cited by
-
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.Sci Rep. 2024 Feb 9;14(1):3318. doi: 10.1038/s41598-024-53862-y. Sci Rep. 2024. PMID: 38337014 Free PMC article.
-
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3. Cochrane Database Syst Rev. 2023. PMID: 38032024 Free PMC article.
-
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.Exp Hematol Oncol. 2023 Jul 27;12(1):66. doi: 10.1186/s40164-023-00426-x. Exp Hematol Oncol. 2023. PMID: 37501090 Free PMC article. Review.
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.Viruses. 2023 Oct 8;15(10):2066. doi: 10.3390/v15102066. Viruses. 2023. PMID: 37896843 Free PMC article.
-
Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.Antiviral Res. 2023 Mar;211:105555. doi: 10.1016/j.antiviral.2023.105555. Epub 2023 Feb 14. Antiviral Res. 2023. PMID: 36791846 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
